Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2773991 | 0.78 | CXCR4 (0.50) | CXCR4NUDT1HRH4SMN1; SMN2 | |
| SCHEMBL13425419 | 0.75 | CRHBP (0.53) | CRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL9073284 | 0.74 | CASP1 (0.58) | HRH4CHRM3PDE4APDE4BPDE4C | |
| SCHEMBL2982745 | 0.74 | L3MBTL1 (0.40) | HRH4CHRM3PDE4APDE4BPDE4C | |
| SCHEMBL9073321 | 0.72 | CASP1 (0.57) | HRH4CHRM3PDE4APDE4BPDE4C | |
| SCHEMBL9182459 | 0.70 | NUDT1 (0.67) | NUDT1HRH4CRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL2773622 | 0.70 | HRH4 (0.44) | CXCR4NUDT1HRH4SMN1; SMN2 | |
| SCHEMBL2775160 | 0.69 | HRH4 (0.43) | CXCR4NUDT1HRH4SMN1; SMN2 | |
| SCHEMBL7718039 | 0.69 | MEN1 (0.56) | CXCR4NUDT1HRH4HDAC1CHRM3 | |
| SCHEMBL2785735 | 0.68 | KMT5A (0.51) | CXCR4NUDT1HRH4HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173910-A1 | TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPDRN PHSTMS D.S.S. (FR) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173910-A1 | TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | CDC25B, CDC25A, CDC25C | CXCR4 1151/4885NUDT1 1139/4885HRH4 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.